PRESSEMITTEILUNGEN

(pressebox) Burgdorf, 14.04.2009, Ypsomed is launching its own reusable Ypsopen® pen system in Poland for the administration of insulin. Starting in the spring of 2009, the Ypsopen® will be distributed in Poland under the name "Ypsopen® Polfa Tarchomin" by the Polish pharmaceutical company Polfa Tarchomin S.A. together with the six Polhumin® insulins (Polhumin R, Polhumin N, Polhumin Mix-2, Polhumin Mix-3, Polhumin Mix-4 and Polhumin Mix-5). In Poland today, 2.7 million people live with diabetes thereof around 1 million are insulin dependent. With the introduction of the Ypsopen® they are being offered a tried-and-tested, user-friendly pen system for the precise and safe administration of insulin.

Richard Fritschi, CEO of Ypsomed, is delighted: "Poland is an important market in Europe with great potential for our own Ypsopen® insulin pen. In the medium-term we have plans to launch the Ypsopen®, which allows for the application of insulin from standard cartridges, in other countries in addition to Poland, Germany and China. Negotiations are ongoing."

In Germany, the Ypsopen® is distributed by Ypsomed through wholesalers and pharmacies and via Ypsomed’s diabetes direct subsidiary DiaExpert, for use with Sanofi-Aventis’ insulins. In China, Ypsomed cooperates with Dongbao, China’s largest insulin manufacturer, which is marketing the Ypsopen® for its own insulins under the name "Dongbao Pen." The Ypsopen®, a high quality metal insulin pen based on tried-and-tested platform technology, provides diabetics with additional functionality to simplify handling. For example the electronic display offers simple operation and ensures that the dose is easy to read.

Trackback URL

1 Million, Burgdorf, Diabetes, Diabetics, Electronic Display, Fritschi, Great Potential, Insulin Pen, Insulins, Medium Term, Negotiations, Pen System, Pharmaceutical Company, Pharmacies, Platform Technology, Poland, Quality Metal, Sanofi Aventis, Wholesalers, Ypsomed